Compare DRD & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRD | AAPG |
|---|---|---|
| Founded | 1895 | 2009 |
| Country | South Africa | China |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | N/A | 2025 |
| Metric | DRD | AAPG |
|---|---|---|
| Price | $36.90 | $25.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $27.50 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 356.0K | 3.9K |
| Earning Date | 02-18-2026 | 03-26-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ 68.66 | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $443,674,785.00 | $54,524,554.00 |
| Revenue This Year | $18.10 | N/A |
| Revenue Next Year | $25.92 | $368.64 |
| P/E Ratio | $25.83 | ★ N/A |
| Revenue Growth | ★ 26.26 | N/A |
| 52 Week Low | $9.51 | $16.50 |
| 52 Week High | $38.20 | $48.45 |
| Indicator | DRD | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 68.25 | 37.99 |
| Support Level | $31.17 | $27.48 |
| Resistance Level | $38.20 | $28.49 |
| Average True Range (ATR) | 1.39 | 0.50 |
| MACD | 0.43 | 0.03 |
| Stochastic Oscillator | 85.17 | 0.00 |
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.